Novo Nordisk A/S
Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four […]
Read More
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product’
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment. CEO […]
Read More
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Copenhagen, DENMARK — Obesity drug giant Novo Nordisk […]
Read More
CNBC Daily Open: Consumers and CFOs alike are expecting a recession in the U.S.
A Forever 21 store in New York, in March 2025. Yuki Iwamura | Bloomberg | Getty Images The shadow of a U.S. recession is growing longer and darkening the outlook for both consumers and CFOs alike, according to various surveys tracking sentiment in March. That said, Wall Street has risen over the past three days […]
Read More
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. […]
Read More
Software giant SAP becomes Europe’s most valuable firm amid German stock market boom
A general view of the headquarters of SAP AG, Germany’s largest software company on January 8, 2013 in Walldorf, Germany. Thomas Lohnes | Getty Images News | Getty Images Software-maker SAP became Europe’s most valuable company this week, riding a wave of artificial intelligence enthusiasm and German stock market gains. The company had a market […]
Read More
Eli Lilly will soon release key data on its weight loss pill. Here’s why it could be a game-changer
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Eli Lilly plans to […]
Read More
Novo Nordisk expands discounted Wegovy to all cash-paying U.S. customers
Jakub Porzycki | Nurphoto | Getty Images Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 per month at their local pharmacy. U.S.-listed shares of Novo fell more than 2.5% to $74.92 in premarket trading. Novo has also lost its spot […]
Read More
Novo Nordisk’s next-gen obesity drug CagriSema had investors excited. Now they’re not so sure
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background. Nurphoto | Nurphoto | Getty Images Novo Nordisk‘s hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from […]
Read More
Zepbound copycats remain online despite FDA ban
This week was supposed to mark the end of compounding pharmacies making copycat versions of Eli Lilly‘s weight-loss drug Zepbound and its diabetes drug Mounjaro. Online, it doesn’t look like much has changed. Popular websites like Amble, EllieMD, Willow and Mochi Health are all still advertising versions of tirzepatide, the active ingredient in Zepbound. Some, […]
Read More